For injectable finished forms, pentazocine lactate is processed into aqueous concentrates at a target strength of 30 mg/mL expressed as pentazocine base. The lactate salt is selected because it disperses rapidly in Water for Injection at 20–25 °C without cosolvent. The solution is held below pH 5.5 to avoid free-base precipitation at the injection site. pH adjustment uses 0.1 M sodium hydroxide or 0.1 M hydrochloric acid after complete dissolution.

Manufacturing equipment includes a jacketed stainless-steel vessel with nitrogen overlay and a bottom-mounted magnetic stirrer. The bulk solution is filtered through a 0.45 µm clarification membrane followed by a 0.22 µm PVDF sterilizing filter. Terminal sterilization at 121 °C for 15 min is acceptable only when loading studies show total impurities not exceeding 0.5%. When thermal degradation data are absent, aseptic filtration and filling under Grade A conditions are used.

Release testing follows USP <71> for sterility, USP <788> for particulate matter in injections, and USP <85> for bacterial endotoxins. Controlled-substance handling is governed by 21 CFR 1308.15 and recordkeeping under 21 CFR 1304.21. The terminal product is a single-dose 1 mL ampoule or a multi-dose 10 mL vial with a suitable preservative. Use is restricted to non-food companion animals because no extrapolated withdrawal period has been established.

What Limits Direct Compression of Low-Dose Pentazocine Hydrochloride Tablets?

Direct compression of low-dose pentazocine hydrochloride is constrained by segregation risk when the active particle size distribution spans more than 100–300 µm and by poor flow when the Carr index exceeds 25%. Published data for pentazocine-specific direct compression is limited. Wet granulation is therefore applied for tablet strengths of 12.5 mg, 25 mg, and 50 mg base equivalent.

A representative formulation uses microcrystalline cellulose at 40–60% w/w, lactose monohydrate at 20–30% w/w, crospovidone at 2–5% w/w, and magnesium stearate at 0.5–1.0% w/w. The binder is a 3–5% w/w solution of HPMC E5 in purified water. Granulation is performed in a high-shear mixer with impeller tip speed 5–10 m/s. Drying proceeds in a fluid-bed dryer at inlet air temperature 55–65 °C until residual moisture is 1.0–2.0%.

Tablet compression is performed on a rotary press with precompression force 3–5 kN and main compression force 8–18 kN. Ejection force is monitored below 1.5 kN to avoid lamination. Quality control includes USP <905> uniformity of dosage units, USP <701> disintegration, and HPLC assay at 90.0–110.0% of label claim. The terminal product is a scored uncoated tablet for oral administration to dogs and non-food horses.

In compounding pharmacies, pentazocine hydrochloride capsules for small companion mammals and avians are produced by geometric dilution. A 1:5 API-to-lactose pre-blend is passed through a 500 µm stainless-steel screen. The pre-blend is then diluted stepwise to a final capsule fill weight of 80–120 mg in size 4 hard gelatin capsules. This method avoids direct high-shear blending of low-dose opioid powder and reduces segregation during capsule filling.

Capsule formulation uses lactose monohydrate as the main diluent and 0.5–1.0% w/w magnesium stearate as lubricant. Because compounded capsules are not enteric-coated, they must not be opened into food unless the prescriber confirms compatibility. Homogeneity testing follows USP <795> and single-capsule assay limits of 90.0–110.0%. Controlled-substance inventory records are maintained under 21 CFR 1304.21.

Terminal product is a hard gelatin capsule containing 0.5–10 mg pentazocine base equivalent for specialty compounding. The capsule format is used when tablet splitting would produce unacceptable dose variance. Published data for this specific veterinary configuration is limited.

When Pentazocine Oral Solutions Require Nitrogen Sparging Instead of Simple pH Adjustment

Simple pH adjustment alone does not protect pentazocine oral solutions from oxidative discoloration during prolonged ambient storage. Nitrogen sparging is introduced when dissolved oxygen exceeds 2 mg/L in the finished vehicle. The solution is prepared cold at 15–20 °C with sodium metabisulfite at 0.05–0.1% w/v and edetate disodium at 0.005–0.01% w/v.

The target concentration is 1–2 mg/mL pentazocine base equivalent in a citrate-buffered vehicle at pH 4.0–4.5. Mixing is performed under vacuum to reduce air entrainment. The solution is filtered through a 0.45 µm nylon membrane and filled into amber Type III glass bottles with child-resistant caps. Terminal product is a multi-dose oral solution for in-clinic dosing of cats and small dogs.

Quality release includes clarity, pH, assay, and microbial enumeration under USP <795>. The product is stored below 25 °C and protected from light. Published stability data for pentazocine oral solutions is limited. A beyond-use date is assigned according to nonsterile compounding risk categories in USP <795>.

For lyophilized injection configurations, freeze-dried pentazocine lactate is prepared as a lyophilized cake in Type I glass vials. The pre-lyophilization solution is formulated at 30 mg/mL base equivalent and filled into 5 mL or 10 mL vials. Freezing is ramped to −40 °C and held for 2–4 h. Primary drying is performed at chamber pressure 100–150 mTorr and shelf temperature −20 °C. Secondary drying is conducted at 25 °C until residual moisture is ≤1.0% by Karl Fischer titration.

After lyophilization, vials are sealed under nitrogen or vacuum. Reconstitution with sterile water for injection yields a clear solution at 30 mg/mL base equivalent. The lyophilized powder format is selected when aseptic processing requires longer holding times prior to terminal assembly. Release testing includes USP <921> water determination, USP <788> particulate matter, and USP <85> bacterial endotoxins.

The terminal product is a single-dose lyophilized injection for reconstitution in companion animals. The powder is not intended for direct oral or topical use. Published data for this specific configuration is limited.

Granule and Premix Configurations Excluded From Feed Administration

Pentazocine granules and premixes are not feed-grade articles and are not authorized for in-feed administration to food-producing species. This restriction is anchored in 21 CFR 530 and EU Regulation (EU) 2019/6. The only legitimate downstream function of a pentazocine premix is as a controlled compounding intermediate in a pharmacy. A 1:10 or 1:100 geometric premix is prepared in a V-blender at 15–25 rpm for 10–15 min.

The premix is packaged in double polyethylene bags inside a rigid outer container. The bulk powder is used to prepare sachet granules for reconstitution or to fill powder papers for small-animal dosing. Homogeneity is assessed by HPLC on 10 sampling points across the blender. The acceptance range is 90.0–110.0% of the theoretical active load. Controlled-substance reconciliation is required under 21 CFR 1304.21.

Medicated feed use would violate Schedule IV inventory requirements and extra-label use restrictions because no withdrawal period has been established. The terminal product is a restricted pharmacy compounding premix, not a finished feed premix. Published data for this specific configuration is limited.